Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced advancements to its unified AI framework for drug target discovery, integrating its previously introduced Target Identification Pro (TargetPro) and Target Identification Benchmark (TargetBench 1.0) into a validated system designed to improve the accuracy, reliability, and scalability of early-stage drug development.
AI drug target platform pairs prediction with benchmarking to improve early discovery
